CompoAtlas

新世代納豆紅麴膠囊食品

新世代納豆紅麴膠囊食品 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
NATTONATTONatto
MONASCUS PURPUREUSMONASCUS PURPUREUSNot identified
GINKGO BILOBA FRUIT POWDERGINKGO BILOBA FRUIT POWDERNot identified
HAWTHORN BERRYHAWTHORN BERRYNot identified
RHODIOLA ROSEA ROOT EXTRACTRHODIOLA ROSEA ROOT EXTRACTNot identified
ACANTHOPANAX SENTICOSUSACANTHOPANAX SENTICOSUSNot identified
SAFFLOWER SEED POWDERSAFFLOWER SEED POWDERNot identified
COENZYME Q10COENZYME Q10Ubiquinone
MAGNESIUM STEARATEMAGNESIUM STEARATENot identified
GELATINGELATINNot identified
TITANIUM DIOXIDETITANIUM DIOXIDENot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1106606062
Chinese name
新世代納豆紅麴膠囊食品
English name
NEW NATTO WITH MONASCUS PURPUREUS HARD CAPSULES
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
九溢國際有限公司
Registration date
2021-07-28
Published validity end
2026-07-28

Original register data

View published fields and their variants
Product name
新世代納豆紅麴膠囊食品
Active ingredients
NATTO;;MONASCUS PURPUREUS;;GINKGO BILOBA FRUIT POWDER;;HAWTHORN BERRY;;RHODIOLA ROSEA ROOT EXTRACT;;ACANTHOPANAX SENTICOSUS;;SAFFLOWER SEED POWDER;;COENZYME Q10;;MAGNESIUM STEARATE;;GELATIN;;TITANIUM DIOXIDE;;
Valid until
1150728
Registration number
1106606062
Licence holder
九溢國際有限公司
Registration date
1100728
Published reference
DHC0B066060623
Published English name
NEW NATTO WITH MONASCUS PURPUREUS HARD CAPSULES

Official source

View the official register, number 1106606062

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • COENZYME Q10
    Read the warning, when it applies and the studies cited

    Coenzyme Q10 (UBIQUINONE-10)

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Rosenfeldt et al. 2007; Singh et al. 1999).

    Sources cited by Health Canada (2)
    • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
    • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial

    Applies to products providing more than 100 mg of Coenzyme Q10 per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).

    Sources cited by Health Canada (3)
    • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
    • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
    • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report

    Condition of application: Migraine prophylaxis/prevention.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.

    Health Canada monograph dated 31 January 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “新世代納豆紅麴膠囊食品”, https://compoatlas.com/en/supplements/taiwan/1106606062-new-natto-with-monascus-purpureus-hard-capsules, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line